Literature DB >> 2038990

Factor XIII subunits in relation to some other hemostatic parameters in ulcerative colitis.

A Stadnicki1, J Kloczko, A Nowak, E Sierka, Z Sliwiński.   

Abstract

The hemostatic parameters, particularly with respect to F.XIII subunits, were examined in 48 untreated UC patients (22 at active and 26 at quiescent stage). UC active patients showed a significant decrease of F.XIII subunit "a," compared with healthy subjects, as well as in UC patients in remission. In contrast, the level of F.XIII subunit "b" in each group was similar. Compared with normal subjects, UC active patients revealed a significant decrease in AT III concentration, prolonged ELT, and elevated fibrinogen level. In addition, the elevated titer of SDPS test for SFMC appeared in approximately 40% of those patients. However, no strict relationship was found between the presence of positive SDPS and diminution of AT III, as well as of F.XIIII subunit "a" in active UC state. In patients in remission, AT III level and ELT were similar to those as in the control group, but fibrinogen concentration was elevated. Such constellation of hemostatic parameters may indicate a tendency to blood hypercoagulability in UC active patients, whereas, in general, these changes are not associated with the stage of remission. The present data may also suggest that F.XIII behavior pattern should be taken into account in the clinical management of UC.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2038990

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  9 in total

Review 1.  Haemostatic system in inflammatory bowel diseases: new players in gut inflammation.

Authors:  Franco Scaldaferri; Stefano Lancellotti; Marco Pizzoferrato; Raimondo De Cristofaro
Journal:  World J Gastroenterol       Date:  2011-02-07       Impact factor: 5.742

2.  Activation of plasma contact and coagulation systems and neutrophils in the active phase of ulcerative colitis.

Authors:  A Stadnicki; M Gonciarz; T J Niewiarowski; J Hartleb; M Rudnicki; N B Merrell; R A Dela Cadena; R W Colman
Journal:  Dig Dis Sci       Date:  1997-11       Impact factor: 3.199

3.  Serum transglutaminase correlates with endoscopic and histopathologic grading in patients with ulcerative colitis.

Authors:  G D'Argenio; V Cosenza; G Riegler; N Della Valle; F Deritis; G Mazzacca
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

4.  Reduced free protein S levels in patients with inflammatory bowel disease: prevalence, clinical relevance, and role of anti-protein S antibodies.

Authors:  S Saibeni; M Vecchi; C Valsecchi; E M Faioni; C Razzari; R de Franchis
Journal:  Dig Dis Sci       Date:  2001-03       Impact factor: 3.199

5.  Differential expression of multiple transglutaminases in human colon: impaired keratinocyte transglutaminase expression in ulcerative colitis.

Authors:  G D'Argenio; M Calvani; N Della Valle; V Cosenza; G Di Matteo; P Giorgio; S Margarucci; O Petillo; F P Jori; U Galderisi; G Peluso
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

6.  Factor XIIIA subunit and Crohn's disease.

Authors:  M Hudson; A J Wakefield; R A Hutton; E A Sankey; A P Dhillon; L More; R Sim; R E Pounder
Journal:  Gut       Date:  1993-01       Impact factor: 23.059

7.  Transglutaminases in Crohn's disease.

Authors:  G D'Argenio; L Biancone; V Cosenza; N Della Valle; F P D'Armiento; M Boirivant; F Pallone; G Mazzacca
Journal:  Gut       Date:  1995-11       Impact factor: 23.059

8.  Systemic and intestinal levels of factor XIII-A: the impact of inflammation on expression in macrophage subtypes.

Authors:  Christoffer Soendergaard; Peter Helding Kvist; Jakob Benedict Seidelin; Hermann Pelzer; Ole Haagen Nielsen
Journal:  J Gastroenterol       Date:  2015-12-11       Impact factor: 7.527

9.  Thrombophilic Risk Factors in Patients With Inflammatory Bowel Disease.

Authors:  Ayten Yazici; Omer Senturk; Cem Aygun; Altay Celebi; Cigdem Caglayan; Sadettin Hulagu
Journal:  Gastroenterology Res       Date:  2010-05-20
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.